

# Sanjay Goel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3735593/publications.pdf>

Version: 2024-02-01

112  
papers

3,643  
citations

236925

25  
h-index

149698

56  
g-index

116  
all docs

116  
docs citations

116  
times ranked

6953  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Incidence of Thrombosis in a Cohort of Cancer Patients with COVID-19. <i>Acta Haematologica</i> , 2022, 145, 152-159.	1.4	6
2	Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. <i>JAMA Network Open</i> , 2022, 5, e2142046.	5.9	9
3	In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis. <i>Computers in Biology and Medicine</i> , 2022, 141, 105110.	7.0	4
4	Medicaid expansion to reduce racial disparity in the incidence of early onset colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 24-24.	1.6	0
5	Long-term avelumab in advanced non-small-cell lung cancer: summaries and <i>post hoc</i> analyses from JAVELIN Solid Tumor. <i>Future Oncology</i> , 2022, 18, 1333-1342.	2.4	1
6	Racial Disparities in COVID-19 Outcomes Among Black and White Patients With Cancer. <i>JAMA Network Open</i> , 2022, 5, e224304.	5.9	43
7	The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <i>Cancer Discovery</i> , 2022, 12, 1282-1293.	9.4	28
8	Assessment of COVID vaccine knowledge and hesitancy in an ethnic minority oncology patient population.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18570-e18570.	1.6	0
9	Intratumoral Injection of <i>Clostridium novyi</i> -NT Spores in Patients with Treatment-refractory Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 96-106.	7.0	59
10	Multiple Myeloma in Hispanics: Incidence, Characteristics, Survival, Results of Discovery, and Validation Using Real-World and Connect MM Registry Data. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e384-e397.	0.4	18
11	Protein Arginine Methyltransferase 5 (PRMT5) and the ERK1/2 & PI3K Pathways: A Case for PRMT5 Inhibition and Combination Therapies in Cancer. <i>Molecular Cancer Research</i> , 2021, 19, 388-394.	3.4	11
12	Racial/ethnic disparities in early-onset colorectal cancer: implications for a racial/ethnic-specific screening strategy. <i>Cancer Medicine</i> , 2021, 10, 2080-2087.	2.8	12
13	Immune-Based Cancer Treatment: Addressing Disparities in Access and Outcomes. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, 66-78.	3.8	23
14	Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. <i>Nature Cancer</i> , 2021, 2, 392-399.	13.2	85
15	Effect of Medicaid expansion on incidence of early-onset colorectal cancer incidence among Hispanics.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3547-3547.	1.6	0
16	Acute thromboembolic events (TE) within 30 days of COVID-19 infection in cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18691-e18691.	1.6	0
17	Expanding the Role of Checkpoint Inhibitors in Immune Cold Tumors. <i>Advances in Oncology</i> , 2021, 1, 85-95.	0.2	0
18	B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, 20, 161-169.	2.3	13

#	ARTICLE	IF	CITATIONS
19	Abstract 961: FGFR3 and eIF4E are overexpressed and interact with PRMT5 and KRAS in CRC. Cancer Research, 2021, 81, 961-961.	0.9	1
20	Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i> . Clinical Cancer Research, 2021, 27, 5236-5247.	7.0	74
21	Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA Oncology, 2021, 7, 1167.	7.1	149
22	Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell, 2021, 39, 1081-1090.e2.	16.8	285
23	Transcriptome Signature of Immune Cells Post Reovirus Treatment in KRAS Mutated Colorectal Cancer. Cancer Management and Research, 2021, Volume 13, 6743-6754.	1.9	4
24	Oncolytic Reovirus (pelareorep) Induces Autophagy in KRAS-mutated Colorectal Cancer. Clinical Cancer Research, 2021, 27, 865-876.	7.0	23
25	Avelumab for platinum-ineligible/refractory recurrent and/or metastatic squamous cell carcinoma of the head and neck: phase Ib results from the JAVELIN Solid Tumor trial. , 2021, 9, e002998.		14
26	Oncolytic Virus Affects the RAS Pathway in Cancer: RNA Sequence Analysis. Journal of Oncology Research and Therapy, 2021, 6, .	0.0	0
27	Therapeutic Targets of KRAS in Colorectal Cancer. Cancers, 2021, 13, 6233.	3.7	6
28	Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer. JAMA Network Open, 2021, 4, e2136378.	5.9	5
29	Multimodal immune activation abilities and characteristics of reovirus.. American Journal of Translational Research (discontinued), 2021, 13, 14176-14185.	0.0	0
30	The Neutrophil-to-Lymphocyte Ratio is a Prognostic Biomarker in An Ethnically Diverse Patient Population with Advanced Pancreatic Cancer. Journal of Gastrointestinal Cancer, 2020, 51, 868-876.	1.3	9
31	Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study. Cancer Discovery, 2020, 10, 1514-1527.	9.4	108
32	Protein Arginine Methyltransferase 5 as a Therapeutic Target for KRAS Mutated Colorectal Cancer. Cancers, 2020, 12, 2091.	3.7	9
33	Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 5358-5367.	7.0	53
34	A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. Cancer Cell, 2020, 38, 761-766.	16.8	26
35	Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. Cancer Discovery, 2020, 10, 935-941.	9.4	643
36	Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice. Cancers, 2020, 12, 1156.	3.7	21

#	ARTICLE	IF	CITATIONS
37	A Phase 1b Dose Escalation Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft-tissue Sarcoma. <i>Clinical Cancer Research</i> , 2020, 26, 4225-4232.	7.0	22
38	A case series of Monoclonal Gammopathy of Undetermined Significance and COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e130-e133.	2.5	15
39	Phase 1 Study to Evaluate the Effect of the Investigational Anticancer Agent Sapanisertib on the QTc Interval in Patients With Advanced Solid Tumors. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 876-888.	1.6	7
40	Immune characterization of metastatic colorectal cancer patients post reovirus administration. <i>BMC Cancer</i> , 2020, 20, 569.	2.6	32
41	Elucidation of Pelareorep Pharmacodynamics in A Phase I Trial in Patients with <i>KRAS</i> -Mutated Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1148-1156.	4.1	22
42	Genomic profiling of prostate cancer at a diverse academic center.. <i>Journal of Clinical Oncology</i> , 2020, 38, 64-64.	1.6	1
43	Molecular Tools for Metastatic Colorectal Cancer Characterization. , 2020, 2, 359-363.		3
44	Differential Efficacy of Anti-VEGF Antibodies Based on Sex and Race in a Diverse Cohort of Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 64-68.	1.3	0
45	The impact of biologic agents in patients with metastatic colorectal cancer by race/ethnicity.. <i>Journal of Clinical Oncology</i> , 2020, 38, 156-156.	1.6	0
46	Clinical characteristics and outcomes of patients with advanced hepatocellular carcinoma treated with immunotherapy: A real-world retrospective study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 557-557.	1.6	0
47	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2499-2511.	2.4	14
48	Anti-PD-1 monoclonal antibody MEDI0680 in a phase I study of patients with advanced solid malignancies. , 2019, 7, 225.		16
49	A phase 1b, multicenter, open-label, dose-finding study of eribulin in combination with carboplatin in advanced solid tumors and non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 567-578.	2.3	1
50	Immunotherapeutic advances in gastrointestinal malignancies. <i>Npj Precision Oncology</i> , 2019, 3, 4.	5.4	16
51	Development and Characterization of a Genetic Mouse Model of <i>KRAS</i> Mutated Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5677.	4.1	3
52	Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 139-144.	1.9	10
53	Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib. <i>Investigational New Drugs</i> , 2019, 37, 948-960.	2.6	27
54	Survival outcome and prognostic model of patients with colorectal cancer on phase 1 trials. <i>Investigational New Drugs</i> , 2019, 37, 490-497.	2.6	4

#	ARTICLE	IF	CITATIONS
55	Racial disparities in clinico-pathological features and survival rates of early-onset colorectal cancer.. Journal of Clinical Oncology, 2019, 37, e15089-e15089.	1.6	1
56	B7-H3 expression by immunohistochemistry as a negative prognostic biomarker in colorectal carcinoma (CRC) in a racially diverse population.. Journal of Clinical Oncology, 2019, 37, e15127-e15127.	1.6	2
57	Characteristics and survival among early onset and standard onset colorectal cancer by race.. Journal of Clinical Oncology, 2019, 37, 522-522.	1.6	1
58	Results of a phase II study to evaluate the safety and efficacy of RX-0201 in combination with everolimus in subjects with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2019, 37, 646-646.	1.6	2
59	Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin. Oncotarget, 2019, 10, 5510-5522.	1.8	13
60	Cost and effectiveness of genetic testing in metastatic colorectal cancer (mCRC) at Montefiore Medical Center (MMC).. Journal of Clinical Oncology, 2019, 37, 643-643.	1.6	0
61	Excision repair cross-complementing group-1 (ERCC1) gene induction in peripheral blood mononuclear cells as a marker of outcome in patients with colorectal cancer treated with oxaliplatin.. Journal of Clinical Oncology, 2019, 37, 542-542.	1.6	0
62	Molecular analysis of advanced colorectal cancer in an ethnically diverse patient population at a single institution.. Journal of Clinical Oncology, 2019, 37, 702-702.	1.6	0
63	Experience with sipuleucel-T in metastatic castration-resistant prostate cancer (mCRPC) with visceral spread from PROCEED.. Journal of Clinical Oncology, 2019, 37, 174-174.	1.6	1
64	Cost and effectiveness of genetic testing in metastatic colorectal cancer (mCRC) at Montefiore Medical Center (MMC).. Journal of Clinical Oncology, 2019, 37, e15043-e15043.	1.6	0
65	Clinicopathologic predictors of worse outcome in early onset colorectal cancer (EO-CRC): A single-institution experience.. Journal of Clinical Oncology, 2019, 37, e15064-e15064.	1.6	0
66	Molecular analysis of advanced colorectal cancer in a patient cohort of Hispanics, African Americans, and Caucasians within a diverse single institution.. Journal of Clinical Oncology, 2019, 37, e15121-e15121.	1.6	0
67	Clinical features and survival among patients with standard-onset versus early-onset colorectal cancer by age groups.. Journal of Clinical Oncology, 2019, 37, 3614-3614.	1.6	0
68	Incidence patterns of early onset colon cancer by race and stage in the US.. Journal of Clinical Oncology, 2019, 37, e18168-e18168.	1.6	0
69	A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 81, 73-80.	2.3	2
70	Patterns of Response and Progression to Immunotherapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 169-178.	3.8	196
71	A Phase II Study of Pelareorep (REOLYSINÂ®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma. Cancers, 2018, 10, 160.	3.7	93
72	Eribulin in non-small cell lung cancer: challenges and potential strategies. Expert Opinion on Investigational Drugs, 2017, 26, 495-508.	4.1	8

#	ARTICLE	IF	CITATIONS
73	Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2017, 16, 286-292.	2.3	6
74	Toll-like receptor 3 as an immunotherapeutic target for KRAS mutated colorectal cancer. <i>Oncotarget</i> , 2017, 8, 35138-35153.	1.8	22
75	Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO. <i>Journal of Oncology Practice</i> , 2017, 13, e62-e67.	2.5	1
76	Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. <i>Oncotarget</i> , 2017, 8, 17313-17327.	1.8	31
77	Randomized phase 1 crossover study assessing the bioequivalence of capsule and tablet formulations of dovitinib (TKI258) in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 921-927.	2.3	1
78	Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors. <i>Investigational New Drugs</i> , 2016, 34, 75-83.	2.6	9
79	Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 1051-1061.	2.3	18
80	Eribulin in Cancer Treatment. <i>Marine Drugs</i> , 2015, 13, 5016-5058.	4.6	53
81	Marine Sponge Derived Eribulin in Preclinical and Clinical Studies for Cancer. , 2015, , 59-100.		1
82	Survival analysis of Hispanics in a cohort of patients with hepatocellular carcinoma. <i>Cancer</i> , 2014, 120, 3683-3690.	4.1	10
83	A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 445-451.	2.6	23
84	Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. <i>Oncotarget</i> , 2014, 5, 2807-2819.	1.8	43
85	Phase Ib extension study of eribulin mesylate in combination with carboplatin in patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2013, 31, e19145-e19145.	1.6	4
86	A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 450-450.	1.6	7
87	Association of telomere length (TL) with clinical outcomes in patients with colorectal carcinoma (CRC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 418-418.	1.6	0
88	Association of telomere length with clinical outcomes in patients with colorectal carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14540-e14540.	1.6	0
89	Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review. <i>Chemotherapy Research and Practice</i> , 2012, 2012, 1-11.	1.6	14
90	Reovirus: A Targeted Therapeutic—Progress And Potential. <i>Molecular Cancer Research</i> , 2012, 10, 1514-1525.	3.4	62

#	ARTICLE	IF	CITATIONS
91	Eribulinâ€”A review of preclinical and clinical studies. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 163-184.	4.4	72
92	Evolution of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 47-58.	4.4	17
93	Rapid screening of SNPs in metastatic colorectal cancer (mCRC) utilizing multiplex sequencing technology (Sequenom).. <i>Journal of Clinical Oncology</i> , 2012, 30, 418-418.	1.6	0
94	The kinetics of the excision repair cross-complementing group-1 (ERCC1) gene in patients with colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14019-e14019.	1.6	0
95	Survival analysis of Hispanics with hepatocellular carcinoma at a large academic institution.. <i>Journal of Clinical Oncology</i> , 2012, 30, e14682-e14682.	1.6	0
96	Intravenous administration of ReolysinÂ®, a live replication competent RNA virus is safe in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2010, 28, 641-649.	2.6	123
97	A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 4207-4212.	7.0	132
98	Alterations of chemotherapeutic pharmacokinetic profiles by drugâ€”drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2009, 5, 109-130.	3.3	10
99	The Effect of Ketoconazole on the Pharmacokinetics and Pharmacodynamics of Ixabepilone: A First in Class Epothilone B Analogue in Late-Phase Clinical Development. <i>Clinical Cancer Research</i> , 2008, 14, 2701-2709.	7.0	27
100	PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab. <i>Cancer Research</i> , 2008, 68, 1953-1961.	0.9	435
101	Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone. <i>Annals of Oncology</i> , 2008, 19, 2048-2052.	1.2	14
102	Novel Orphan Nuclear Receptors-Coregulator Interactions Controlling Anti-Cancer Drug Metabolism. <i>Current Drug Metabolism</i> , 2008, 9, 611-613.	1.2	19
103	Pharmacokinetic and safety study of subcutaneously administered weekly ING-1, a human engineeredâ„¢ monoclonal antibody targeting human EpCAM, in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2007, 18, 1704-1707.	1.2	20
104	Pharmacokinetic and safety study of weekly irinotecan and oral capecitabine in patients with advanced solid cancers. <i>Investigational New Drugs</i> , 2007, 25, 237-245.	2.6	7
105	EGFR inhibitor-mediated apoptosis in solid tumors. <i>Journal of Experimental Therapeutics and Oncology</i> , 2007, 6, 305-20.	0.5	29
106	A phase I safety and dose escalation trial of docetaxel combined with GEMÂ®231, a second generation antisense oligonucleotide targeting protein kinase A R1Î± in patients with advanced solid cancers. <i>Investigational New Drugs</i> , 2006, 24, 125-134.	2.6	33
107	A phase I safety and dose escalation trial of docetaxel combined with GEMÂ®231, a second generation antisense oligonucleotide targeting protein kinase A R1Î± in patients with advanced solid cancers. <i>Investigational New Drugs</i> , 2006, 24, 125.	2.6	1
108	A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancer. <i>Investigational New Drugs</i> , 2003, 21, 103-107.	2.6	29

#	ARTICLE	IF	CITATIONS
109	Erlotinib (Tarceva®): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Review of Anticancer Therapy, 2003, 3, 269-279.	2.4	43
110	A safety study of a mixed-backbone oligonucleotide (GEM231) targeting the type I regulatory subunit alpha of protein kinase A using a continuous infusion schedule in patients with refractory solid tumors. Clinical Cancer Research, 2003, 9, 4069-76.	7.0	15
111	Phase I Clinical Trial of Irinotecan With Oral Capecitabine in Patients With Gastrointestinal and Other Solid Malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2002, 25, 528-534.	1.3	10
112	Tyrosine kinase inhibitors: A clinical perspective. Current Oncology Reports, 2002, 4, 9-19.	4.0	43